DK1703902T3 - Memantin til behandling af mild til moderat Alzheimer's sygdom - Google Patents

Memantin til behandling af mild til moderat Alzheimer's sygdom

Info

Publication number
DK1703902T3
DK1703902T3 DK05711256.7T DK05711256T DK1703902T3 DK 1703902 T3 DK1703902 T3 DK 1703902T3 DK 05711256 T DK05711256 T DK 05711256T DK 1703902 T3 DK1703902 T3 DK 1703902T3
Authority
DK
Denmark
Prior art keywords
mild
disease
memantine
treatment
moderate alzheimer
Prior art date
Application number
DK05711256.7T
Other languages
English (en)
Inventor
Scott Mcdonald
Ivan Gergel
Albrecht Stoeffler
Hans-Joerg Moebius
Yvonne Wirth
Steven Potkin
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34798833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1703902(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Application granted granted Critical
Publication of DK1703902T3 publication Critical patent/DK1703902T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK05711256.7T 2004-01-05 2005-01-05 Memantin til behandling af mild til moderat Alzheimer's sygdom DK1703902T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53455304P 2004-01-05 2004-01-05
US54217604P 2004-02-04 2004-02-04
PCT/US2005/000145 WO2005067908A2 (en) 2004-01-05 2005-01-05 Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease

Publications (1)

Publication Number Publication Date
DK1703902T3 true DK1703902T3 (da) 2011-02-14

Family

ID=34798833

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05711256.7T DK1703902T3 (da) 2004-01-05 2005-01-05 Memantin til behandling af mild til moderat Alzheimer's sygdom

Country Status (17)

Country Link
US (2) US20060020042A1 (da)
EP (1) EP1703902B1 (da)
AT (1) ATE486592T1 (da)
AU (1) AU2005204358B2 (da)
CA (1) CA2551689A1 (da)
CY (1) CY1111359T1 (da)
DE (1) DE602005024511D1 (da)
DK (1) DK1703902T3 (da)
HR (1) HRP20110035T1 (da)
IL (1) IL176689A0 (da)
NZ (1) NZ548327A (da)
PL (1) PL1703902T3 (da)
PT (1) PT1703902E (da)
RS (1) RS51540B (da)
RU (1) RU2371173C2 (da)
SI (1) SI1703902T1 (da)
WO (1) WO2005067908A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
AU2006261082B2 (en) * 2005-06-22 2012-04-19 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
CA2651898A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
EP2056876A1 (en) * 2006-08-21 2009-05-13 Novartis AG Biomarkers for alzheimer's disease progression
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
CA2706203A1 (en) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
BRPI0918971A2 (pt) 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
ES2562959T3 (es) * 2010-02-26 2016-03-09 Evotec International Gmbh Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
MX2012009735A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US20140350380A1 (en) * 2011-09-19 2014-11-27 The Feinstein Institute For Medical Research Identification and uses of brain activity networks
JP5404750B2 (ja) * 2011-11-22 2014-02-05 シャープ株式会社 認知症ケア支援方法、認知症情報出力装置、認知症ケア支援システム、及びコンピュータプログラム
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2014015047A1 (en) 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
KR20150064743A (ko) 2012-10-05 2015-06-11 트랜스테크 파르마 엘엘씨 경도 및 중등도 알츠하이머 병의 치료
WO2015006643A2 (en) * 2013-07-12 2015-01-15 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7402225B2 (ja) 2018-05-11 2023-12-20 ロード アイランド ホスピタル ヌクレオシド系逆転写酵素阻害剤を用いて関節障害を処置するための組成物および方法
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
US20210002650A1 (en) * 2019-07-03 2021-01-07 University Of Virginia Patent Foundation Compositions and methods for treating alzheimer's disease
KR102271305B1 (ko) * 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
EP4190319A4 (en) 2020-07-29 2024-05-01 Novamedica Limited Liability Company Pharmaceutical composition comprising memantine and citicoline
KR102272907B1 (ko) * 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
JP2025520781A (ja) * 2022-06-24 2025-07-03 アリバイオ カンパニー リミテッド 神経変性疾患の予防及び治療のための組成物及び方法
WO2024003784A1 (en) * 2022-06-29 2024-01-04 Aribio Co., Ltd. Composition for preventing and treating neurodegenerative diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (da) * 1972-04-20 1973-10-23
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE10299048I2 (de) * 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5958919A (en) * 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
UA61962C2 (uk) * 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
GB9806513D0 (en) * 1998-03-26 1998-05-27 Phytopharm Ltd Membrane-bound receptors
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
EP1509232B1 (en) * 2002-05-31 2008-11-19 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES

Also Published As

Publication number Publication date
RU2371173C2 (ru) 2009-10-27
RS51540B (sr) 2011-06-30
PT1703902E (pt) 2010-11-17
US20060020042A1 (en) 2006-01-26
US20100048726A1 (en) 2010-02-25
PL1703902T3 (pl) 2011-04-29
CA2551689A1 (en) 2005-07-28
AU2005204358A1 (en) 2005-07-28
HRP20110035T1 (hr) 2011-02-28
AU2005204358B2 (en) 2008-09-04
EP1703902B1 (en) 2010-11-03
NZ548327A (en) 2009-06-26
CY1111359T1 (el) 2015-08-05
WO2005067908A3 (en) 2005-11-10
SI1703902T1 (sl) 2011-02-28
RU2007129842A (ru) 2009-02-10
IL176689A0 (en) 2006-10-31
WO2005067908A2 (en) 2005-07-28
EP1703902A2 (en) 2006-09-27
DE602005024511D1 (de) 2010-12-16
ATE486592T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
TW200716208A (en) Modified and immediate release memantine bead formulation
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
WO2008005534A3 (en) Orally dissolving formulations of memantine
MX2007001679A (es) Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
BR0104830A (pt) Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
DK1915620T3 (da) Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
TW200740452A (en) Therapeutic gastrodia extracts
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
DK1786442T3 (da) Behandling af neurodegenerative sygdomme under anvendelse af DEGS-inhibitorer
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение
WO2007031878A3 (en) Methods of treating nervous disorders
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
SG153698A1 (en) Composition and method for prevention and treatment of alzheimeræs disease
TW200501958A (en) A therapeutic agent for treating a behavioral disorder